The CRO sector rebounded with Wanbang Pharmaceuticals up more than 15%, Haoyuan Pharmaceuticals and Pharmaron up more than 5%, and Wuxi AppTec, Pharma Block Sciences, Hongbo Pharmaceuticals, and Asymchem Laboratories leading the way in increase percentage. Recently, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded. According to statistics, this year's ASCO Annual Meeting collected 426 studies as oral presentations, of which 55 were from China. This data has doubled compared to 2023, setting a new record.
CRO板块震荡反弹 万邦医药涨超15%
CRO sector rebounds shock, Wanbang Pharmaceutical rises more than 15%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated